



Sixth International  
Joint Meeting on  
**THORACIC  
SURGERY**  
Barcelona - 20<sup>th</sup>, 21<sup>st</sup> and 22<sup>nd</sup> November 2024  
Auditorio Foment del Treball Nacional, Barcelona (Spain)

11<sup>th</sup> International Meeting on General Thoracic Surgery



Hospital  
Universitari  
Sagrat Cor

10<sup>th</sup> International Workshop on Surgical Exploration of the  
Mediastinum and Systematic Nodal Dissection



5<sup>th</sup> Meeting of the Thoracic Oncology, Thoracic  
Surgery, Techniques & Transplant, Respiratory Nursing  
and Respiratory Physiotherapy Areas of the Spanish  
Society of Pneumology and Thoracic Surgery (SEPAR)



3<sup>rd</sup> Joint Meeting of the Spanish Society of  
Thoracic Surgery (SECT)



30<sup>th</sup> Congress of the "Asociación Iberoamericana  
de Cirugía Torácica" AIACT



10<sup>th</sup> International Workshop on Surgical Exploration of the  
Mediastinum and Systematic Nodal Dissection



## DEFINITIONS AND PATIENT SELECTION

Isabelle Opitz

*University Hospital Zürich, Department of Thoracic Surgery, Zürich, Switzerland*

Pleural mesothelioma remains a difficult to treat and very heterogeneous oncological disease and the incidences are still rising. Surgery plays a role in diagnosis, cytoreduction and palliation for the treatment of MPM. At this stage, macroscopic complete resection within multimodality treatment offers longest survival for selected patients and is currently recommended across international guidelines, lung-sparing techniques are favored over extrapleural. MARS 2 is the first RCT comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication after chemotherapy for patients with malignant pleural, however, in an unselected patient population.

Nivolumab plus ipilimumab is now indicated as a first-line treatment for unresectable MPM in many countries after Checkmate 743. Chemoimmunotherapy is emerging as a next step with results from three pivotal phase III trials in the frontline setting.

Understanding the disease heterogeneity and selecting best candidates for combined treatment based on clinical, pathological and biological factors, ideally in a trial setting should be the way forward.

## Literature:

- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Stermann D, Thomas A, Hassan R. *J Clin Oncol*. 2018 May 1;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394. Epub 2018 Jan 18.
- ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Opitz I, Scherpereel A, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruyscher D, Durieux V, Faivre-Finn C, Fennell DA, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Paireon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Putora PM, Cardillo G. *Eur J Cardiothorac Surg*. 2020 Jul 1;58(1):1-24. doi: 10.1093/ejcts/ezaa158.
- Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lim E, Waller D, Lau K, Steele J, Pope A, Ali C, Bilancia R, Keni M, Popat S, O'Brien M, Tokaca N, Maskell N, Staddon L, Fennell D, Nelson L, Edwards J, Tenconi S, Socci L, Rintoul RC, Wood K, Stone A, Muthukumar D, Ingle C, Taylor P, Cove-Smith L, Califano R, Summers Y, Tasigiannopoulos Z, Bille A, Shah R, Fuller E, Macnair A, Shamash J, Mansy T, Milton R, Koh P, Ionescu AA, Treece S, Roy A, Middleton G, Kirk A, Harris RA, Ashton K, Warnes B, Bridgeman E, Joyce K, Mills N, Elliott D, Farrar N, Stokes E, Hughes V, Nicholson AG, Rogers CA; MARS 2 Investigators. *Lancet Respir Med*. 2024 Jun;12(6):457-466. doi: 10.1016/S2213-2600(24)00119-X. Epub 2024 May 10.
- First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas P. *Lung Cancer*. 2022 May;167:8-16. doi: 10.1016/j.lungcan.2022.03.012. Epub 2022 Mar 21.